Revisión
URI permanente para esta colección
Examinar
Examinando Revisión por Materia "http://purl.org/pe-repo/ocde/ford#3.00.00"
Mostrando 1 - 5 de 5
Resultados por página
Opciones de ordenación
Ítem Acceso Abierto Diseño, construcción y validación inicial de un instrumento de medición para la evaluación de resúmenes para presentaciones en congresos [Assessment of summaries presented in congresses. Study of validation](Sociedad de Cirujanos de Chile, 2016) Manterola, C.; Otzen, T.Objective: The aim of this article is to present the new instrument for evaluating congress abstracts of SCCh, in use from 2014, so as to standardize its application item by item. Material and method: Two-stage study with qualitative methodology for generating items and construction of the measuring instrument. In the first stage a collection of items was based on a review of the literature. In the second, the instrument was built by applying reduction items through a panel of experts. Thus, content validity was determined. The expert panel consisted of 6 members. Three clinical epidemiologists and three members of the SCCh. All with Master’s degree or PhD and research experience. Qualitative strategy is applied by Delphi technique; after the draft was presented to a panel of experts other than the above, at a meeting of ad-hoc working group, organized by the SCCh; at which time the proposal was discussed, the wording of items and domains was refined based on examples and the final instrument defined. Results: The items generated in the first stage (n = 15), who finished with the second draft; were grouped into 5 domains: introduction, material and method, results, conclusion, importance, originality and interest of the study; and overall presentation. When applying the questionnaire to the second panel of experts, a reduction items was generated and an item is added. Thus, the final instrument was composed of 10 items, grouped into 6 domains was constructed. Conclusion: A detailed description of the scale and guidelines for its implementation is presented, which will confer adequate reliability of the measurements. © 2016 Sociedad de Cirujanos de Chile.Ítem Acceso Abierto Extensively drug-resistant tuberculosis: Report and literature review on two cases requiring prolonged treatment(Medical Science International, 2016) Matos-Tocasca, M.; de La Cruz-Ku, G.; Auccacusi, E.; Fernandez-Salas, D.; García-Ahuanari, T.; Valcarcel-Valdivia, B.Objective: Unusual clinical course Background: Extensively drug-resistant tuberculosis (XDR-TB) is a global problem due to the high morbidity and mortality it causes. Peru is one of the countries with the highest numbers of cases of XDR-TB, which increase every year. Case Report: We present the case of two siblings who developed XDR-TB, underwent surgery twice, and were in individualized treatment for more than 6 years. Finally they achieved remission of symptoms, despite not having standardized treatment schemes during their diagnosis period. Conclusions: Extensively drug-resistant tuberculosis can be cured with a treatment that involves both medical care and patient actions to achieve remission of the disease. © Am J Case Rep.Ítem Acceso Abierto Ingesta de arsénico: el impacto en la alimentación y la salud humana [Arsenic intake: impact in human nutrition and health](Instituto Nacional de Salud, 2018) Medina-Pizzali, M.L.; Robles, P.; Mendoza, M.; Torres, C.Arsenic is an element that is widely distributed throughout the environment. Its compounds are mainly in the state of pentavalent and trivalent oxidation; and in inorganic and organic forms. Arsenical species vary in their degree of toxicity, with inorganic compounds being more toxic than organic and trivalent compounds more toxic than pentavalent compounds. There would be interconversion between the less toxic species and other more toxic species and the cooking and processing methods could affect it. Arsenic is a carcinogenic agent and causes multiple negative effects on human health in the short and long term. Non-occupational human exposure to arsenic occurs mainly through water and food. The regulation is variable for each country and is based on WHO standards, the Codex Alimentarius, and the European Union. Many studies focus on determining the total arsenic content but do not identify arsenical species in foods. Globally, fish and seafood, chicken, meat, rice, and seaweed have high levels of arsenic. In Peru, there are few studies on total arsenic content and arsenical species in food despite the fact that we have areas with high levels of environmental contamination. The objective of this review is to discuss exposure to arsenic through food and water intake, related regulations, toxicity, consequences on human health and main foods that contribute to its intake. © 2018, Instituto Nacional de Salud. All rights reserved.Ítem Acceso Abierto Systemic lupus erythematosus: a therapeutic challenge for the XXI century(Springer-Verlag London Ltd, 2014) Ugarte-Gil, M.F.; Alarcón, G.S.Despite significant advances in our understanding of the pathogenesis of systemic lupus erythematosus (SLE), there are only a few drugs approved by the regulatory agencies across the world for the treatment of these patients; in fact, many of the compounds subjected to clinical trials have failed in achieving their primary endpoints. Current therapeutic options include antimalarials which should be used in all SLE patients unless they are strongly contraindicated, glucocorticoids which should be used at the lowest possible dose and for the shortest possible time, and immunosuppressive drugs which should be used judiciously, mainly in patients with severe organ involvements or receiving high doses of steroids to control their disease. Despite improvement on the survival of SLE patients, damage accrual has not varied over the last few decades, reflecting a gap between these therapeutic options and the expectations of these patients and their treating physicians. Biologic compounds can be used in some refractory cases. However, their cost is of great concern for both the patients and the health system. Cost is of special importance in low-income countries, because low-income SLE patients tend to experience a more severe disease having an overall worse prognosis which is compounded by their limited access to the health system. Although a treatment to target based on defined molecular pathways for specific disease subsets is appealing, this is not yet a reality. This review addressed current therapeutic options for SLE patients and the state of the art of investigational drugs targeting pathogenic pathways identified in these patients. © 2014 Clinical Rheumatology.Ítem Acceso Abierto Therapeutic actions of the thiazolidinediones in Alzheimer's disease(Hindawi Publishing Corporation, 2015) Pérez, M.J.; Quintanilla, R.A.Alzheimer's disease (AD) is a multifactorial metabolic brain disorder characterized by protein aggregates, synaptic failure, and cognitive impairment. In the AD brain is common to observe the accumulation of senile plaques formed by amyloid-beta (Aβ) peptide and the neurofibrillary tangles composed of modified tau protein, which both lead to cellular damage and progressive neurodegeneration. Currently, there is no effective therapy for AD; however several studies have shown that the treatments with the peroxisome proliferators activated receptor-gamma (PPARγ) agonists known as thiazolidinedione drugs (TZDs), like rosiglitazone and pioglitazone, attenuate neurodegeneration and improve cognition in mouse models and patients with mild-to-moderate AD. Furthermore, studies on animal models have shown that TZDs inhibit neuroinflammation, facilitate amyloid-β plaque clearance, enhance mitochondrial function, improve synaptic plasticity, and, more recently, attenuate tau hyperphosphorylation. How TZDs may improve or reduce these pathologic signs of AD and what the mechanisms and the implicated pathways in which these drugs work are are questions that remain to be answered. However, in this review, we will discuss several cellular targets, in which TZDs can be acting against the neurodegeneration. © 2015 María José Pérez and Rodrigo A. Quintanilla.